Search
Bucrylate
go.drugbank.com/drugs/DB19727ExperimentalBucrylate is a small molecule drug. Bucrylate has a monoisotopic molecular weight of 153.08 Da.
Categories: Compounds used in a research, industrial, or household settingAmmonium trichlorotellurate
go.drugbank.com/drugs/DB17740InvestigationalAmmonium trichlorotellurate is an investigational compound with anti-tumour [A259147] and anti-inflammatory properties.[A259152]
Synonyms: Ammonium trichloro [dioxoethylene-O,O') tellurium (IV), Ammonium trichloro(dioxyethylene-o,o')tellurium(iv)Categories: Compounds used in a research, industrial, or household settingMIV-701
go.drugbank.com/drugs/DB05736ExperimentalMIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalIn response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.
Categories: Interferon Type ISynonyms: alb-IFNSodium sulfate
go.drugbank.com/drugs/DB09472ApprovedInvestigationalVet approvedSodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. … Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalIt is used to treat Macular degeneration. … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.
AME-527
go.drugbank.com/drugs/DB05879ExperimentalAME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.
Imexon
go.drugbank.com/drugs/DB05003InvestigationalImexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. … Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated